



Exam Papers Practice

Boost your performance and confidence with these topic-based exam questions

Practice questions created by actual examiners and assessment experts

Detailed mark schemes

Suitable for all boards

Designed to test your ability and thoroughly prepare you

6.3 Defence Against Infectious Disease



IB Biology - Revision Notes

www.exampaperspractice.co.uk

6.3.1 Skin

Skin

- The **skin and mucous** membranes form a **primary defence** against pathogens that cause infectious disease
- **Skin** is the largest organ of the body and is covered in **microorganisms** that usually cause no issues, as they can't enter the body. Skin provides:
 - A **tough physical barrier** that prevents entry of pathogens into our bodies
 - Cuts in the skin are sealed by formation of **blood clots** to prevent entry of pathogens
 - **Chemical protection** through the production of **sebum** from the sebaceous glands of the hair follicles
 - Sebum is a chemical responsible for maintaining a **low skin pH** which inhibits the growth of microorganisms
- **Mucous membranes** are found lining vulnerable areas which may be a route for pathogens into the body
 - This includes the **airways**, areas around the **reproductive organs** (foreskin and vagina) and the **digestive system**
- The membranes contain goblet cells which produce mucus containing **glycoproteins**
 - Microorganisms and particles become **trapped** by the mucus and are then either **swallowed** (into the stomach) or **expelled**, therefore preventing infection
 - Mucus also contains **lysozyme enzymes** which have **antibacterial** properties, providing more protection from invading microorganisms

Exam Papers Practice


Copyright

© 2024 Exam Papers Practice

6.3.2 Blood Clotting

Platelets


- When the skin is cut, microorganisms have an entry point to get into the body
 - The first line of defence is compromised
- In order to minimise the risk of substantial **blood loss** and entry of **unwanted microorganisms**, the blood starts to clot to **seal the wound**
- In response to **blood vessel damage**, platelets form a temporary **plug** to stem bleeding
 - Platelets are **cellular fragments** that make up one component of the blood
- They release chemicals called **clotting factors** that trigger a **chemical cascade** which results in blood clotting



The blood is made up of 4 key components including plasma, red blood cells, white blood cells and platelets


Blood Clotting Proteins

- The chemical cascade, triggered by the clotting factors, involves a large number of steps and several plasma proteins
 - First of all, the **clotting factors** stimulate the release of the enzyme **thrombin**
 - Thrombin catalyses the conversion of the soluble protein **fibrinogen** into **fibrin**, which is insoluble
 - Fibrin forms a **mesh** that traps more platelets and blood cells to prevent entry through the wound
 - A small initial stimulus is **amplified** to produce a large amount of fibrin so that the wound is quickly sealed
- Exposure to air results in the hardening of the mesh to create a **scab**



Copyright

© 2024 Exam Papers Practice



Exam Papers Practice

Copyright © 2024 Exam Papers Practice

Blood clot formation

Clotting in Coronary Arteries

Causes of blood clots in the coronary arteries

- A blood clot in the coronary arteries is called **coronary thrombosis**
- Several factors may **increase the risk** of coronary thrombosis developing:
 - **Atherosclerosis in the coronary arteries** results in a build-up of layers of fatty material (plaque) causing **damage to the endothelium wall**
 - Bulging of **the lumen** of the artery causes a blockage which reduces the space for blood flow
 - Deposition of **calcium ions** can worsen the situation by hardening the endothelium
 - **Lesions** can also sometimes form due to **ruptures** in the atheroma

Consequences of blood clot formation in the coronary arteries

- **Occlusion** of the **coronary arteries** is a common problem that can lead to significant health issues such as **coronary heart disease**
- The coronary arteries deliver **oxygen** and **nutrients** to the cardiac muscle tissue
- If a blood clot forms in the coronary arteries, it can cause **blockages**
- A blockage means that the tissue beyond that point is deprived of oxygen and nutrients, so it is unable to **respire aerobically**
- As a result, cells are unable to produce a **sufficient amount of ATP** which inhibits normal cardiac muscle contraction resulting in **irregular** and **uncoordinated** movement called **fibrillation**
 - If not rectified, either naturally or through medical intervention, fibrillation could lead to **death**
- A **heart attack** (myocardial infarction) may also occur in situations where the blood supply is completely inhibited so that the cardiac muscle tissue starts to die
 - This can be fatal

Risk factors for coronary thrombosis

- There are several factors which have shown a clear **correlation** with increased chances of coronary thrombosis or heart attacks
- The main risk factors for include:
 - **Genetic factors**
 - **Age and sex**
 - **High blood pressure**
 - **Smoking**
 - **High concentrations of low-density lipoproteins (LDLs)**
 - **Diabetes**
 - **Obesity**
 - **Lack of exercise**


Exam Tip

Remember, **correlation does not prove causation**: There are many contributing factors which will affect the likelihood of developing a coronary thrombosis, as a result, we cannot say that any single factor is **causative**. We can say that there is a **correlation** between that factor and the incidence of coronary thrombosis

6.3.3 White Blood Cells

White Blood Cells

- **Phagocytes** are white blood cells that are produced continuously in the **bone marrow**
- They are responsible for **removing dead cells and invasive microorganisms**; a **non-specific immune response**
- Phagocytes move to the site of infection and attach to pathogens
- The **cell surface membrane** of the phagocyte extends out and around the pathogen, **engulfing it by endocytosis**
- They then digest the pathogen using **enzymes** which are stored within **lysosomes** (in their cytoplasm)




Copyright

© 2024 Exam Papers Practice

Phagocytic cells ingest pathogens and digest them using enzymes

Antibody Production

- Pathogens possess protein molecules on their cell membranes called **antigens**
- When a **lymphocyte** is exposed to a specific foreign antigen, it will produce specific **antibodies**
 - It is known as a **specific immune response** because one lymphocyte will respond to just **one type of antigen**
- Antibodies have two functional regions:
 - A hypervariable functional region that binds to antigens on pathogens
 - A functional region which aids the body in fighting the pathogen by **labelling the pathogen** (making it easier for phagocytes to find and engulf) and by **preventing virus cells from binding** to receptors on host cells (meaning they cannot enter the cell)
- When activated by a pathogen, lymphocytes clone themselves to produce **plasma cells** which are capable of mass **antibody production**
- Antibodies are only short-lived, degrading within weeks or months and the plasma cells that produced them are lost soon after
- However, **inactive long-living memory cells** are produced which remain in the blood for a long period of time to give **immunity**
- Memory cells allow for the **rapid production of antibodies** after secondary infection
 - If the same pathogen infects for a second time, the inactive **memory cells** will become active and divide to produce **plasma cells** at a rapid rate
 - These plasma cells are able to supply a **large number of antibodies at a rapid rate** to fight the pathogen before symptoms appear



Memory cells allow for the rapid production of antibodies

Effects of HIV on Antibody Production

- **Human Immunodeficiency Virus** is a retrovirus made up of several key components including **RNA** and the enzyme, **reverse transcriptase**, which is used to produce DNA in the host cell
- HIV infects the body and attacks a type of lymphocyte cell called a **T-helper cell**
- T-helper cells are a key component in the production of antibodies, so HIV **inhibits the bodies capacity to produce antibodies**
- In the **early stages of infection**, antibodies are produced to fight HIV, these can be **detected in blood tests**
 - The individual is said to be **HIV positive**

The development of AIDS

- As the **infection progresses**, the ability to produce antibodies significantly reduces
- This renders the immune system unable to fight off other pathogens and so the individual becomes **prone to infection** from other **opportunistic pathogens**
- When the individual is suffering from **several diseases** or conditions at the same time, they are said to have **acquired immune deficiency syndrome (AIDS)**
- **Progression of HIV**, from the initial infection to the development of AIDS, can be slowed down using **anti-retroviral drugs**
 - Due to highly successful drugs, many HIV positive individuals are able to live full-quality lives with normal life expectancies

Transmission of HIV

- HIV is unable to survive outside of the human body and so is mainly **transmitted by the direct exchange of body fluids**
 - Viruses need host cells in order to replicate
- This means HIV can be transmitted in the following ways:
 - **Sexual intercourse**
 - **Blood donation**
 - **Sharing of needles** used by intravenous drug users
 - From mother to child **across the placenta**
 - Mixing of blood between mother and child **during birth**
 - From mother to child **through breast milk**


Copyright

© 2024 Exam Papers Practice

6.3.4 Antibiotics

Antibiotics


- **Antibiotics** are **drugs** that **inhibit the growth** of microorganisms
 - Most antibiotics **kill or stop the growth of bacteria** (prokaryotes) but do not harm the cells of the infected organism
 - This is because they block specific processes that occur in **prokaryotic cells** but **do not have the same effect on eukaryotic cells**
- Processes that might be targeted include:
 - Transcription
 - Translation
 - DNA replication
 - Ribosome function
 - Cell wall formation
- Some antibiotics are derived from living organisms such as saprotrophic fungi
 - **Penicillin** is produced by certain fungi in the genus *Penicillium*
 - When growing in the wild the antimicrobial secretions of the fungus helps it to **compete** by killing nearby saprotrophic bacteria
- Antibiotics can also be made synthetically (in a laboratory)



- Penicillin is not effective against **all bacteria** (eg. *tuberculosis*) because the bacteria may have:
 - **Thicker cell walls** which reduce permeability
 - **Enzymes which breakdown penicillin**
- There are many different examples of antibiotics which are effective against a range of bacterial diseases

Florey & Chain's Experiments

- **Howard Florey and Ernst Chain** carried out experiments to test penicillin on bacterial infections in mice in the 1930s
- First of all, they developed a technique for **purifying and concentrating** penicillin from liquid cultures of *Penicillium*
 - The method they used was very **inefficient** and only produced small quantities of the antibiotic
- Secondly, they showed that Penicillin was effective in preventing bacterial growth on agar plates
- After they had collected this evidence, Florey and Chain used mice to show the effect of penicillin at the level of an organism
 - In order to carry out these tests on mice, the mice first needed to be **infected** with a known bacterial pathogen. A deadly ***Streptococcus* bacteria** was used to develop pneumonia in 8 mice
 - Of these 8 mice, 4 were **injected with penicillin** and 4 were left **untreated**
 - In less than 24 hours, the 4 untreated mice had **all died** whereas those that were treated with penicillin **survived**



Florey and Chain showed that penicillin could aid the recovery of mice infected with *Streptococcus* bacteria


Human tests

- After successful trials using penicillin to treat mice, Florey and Chain were ready to begin testing **human patients**
- It took some time to build up a **large enough supply of penicillin** using their purification techniques
- They then started treatment on their first patient, a policeman who was suffering from a life-threatening bacterial infection resulting from a scratch on his face
- The patient showed improvement but unfortunately, the supply of penicillin was **not enough to complete the treatment** and so the man died of his infection
- Following this, a series of other patients were treated with varying success and Florey and Chain realised that they needed to produce much larger quantities of penicillin than their current capacity
- Larger scale testing and treatment (using penicillin) became possible after an **American pharmaceutical company started mass production**
- It was after this that the true level of efficacy for penicillin was established

Florey & Chain's Experimental Technique

NOS: Risks associated with scientific research; Florey and Chain's tests on the safety of penicillin would not be compliant with current protocols on testing

- New drugs carry new risks as scientists can not always predict how the body may **respond** to the drug, whether the drug will be **effective** or how significant any **side effects** might be
- Before drugs become licenced and available for use, they must go through a rigorous series of tests and trials to **minimise the risks**
- A summary of the procedure is as follows:
 - Initially, after a computer analysis has been carried out on the structure of the drug, trials are carried out with **animals** to see the effect on a whole organism level
 - Next, a **small number of healthy humans** will trial the drug to measure the **toxicity**
 - If these first 2 stages are successful, testing will be carried out on a progressively larger number of **patients** suffering from the target disease
 - In this final stage, the aim is to establish how **effective** the drug is and collect as much information as possible about **side effects**
 - Once the clinical trials are complete, the new drug can be **approved and licenced** for medical use
 - The process usually takes **years** to reach the approval stage
- When Florey and Chain carried out their trials with penicillin, these protocols for safe testing were not in place and their work was only carried out over a matter of **months**
 - This meant that some patients received **treatment very rapidly** for infections that were previously incurable, however, there was a **huge risk** that the new drug, penicillin, could have caused **significant side effects**



New drugs go through a series of tests and trials in order to be approved for medical use

Previous drugs trials

- Carefully designed drugs testing protocols do now exist, but serious problems can still arise
 - **Thalidomide** was a drug that was used in the 1950s to treat a variety of conditions including some cancers and leprosy
 - It was found that thalidomide provided an effective cure for **morning sickness** and so pregnant women were prescribed thalidomide as a treatment
 - The effects of the drug **on a foetus** had **not been tested** and in subsequent years, babies were born with a **range of disabilities** including the absence of limbs, sensory impairment and disfigurement, amongst others
 - It took several years for the link to be made between Thalidomide and the disabilities of the thousands of children who were born
 - Thalidomide was **withdrawn** from use in the early 1960's
 - A drugs trial was carried out in 2006 to test an experimental **leukaemia drug, TGN1412**
 - The drug had **successfully passed the animals trials** where it was given to monkeys, so it moved to the next stage of testing
 - Eight healthy volunteers took part in the trial and after an hour of receiving the drug, six of them were rushed to **intensive care with multiple organ failure**
 - Although they all recovered, the **long term effects** on their immune systems are unknown
 - This is one of the most infamous clinical trial emergencies of modern day

Copyright

© 2024 Exam Papers Practice

Viruses

Antibiotics and viruses


- Antibiotics are ineffective against **viruses** as they are **non-living**
- Viruses are **particles** and not cells
 - They have **no metabolism** or cell structure and therefore cannot be targeted in any of the ways that antibiotics target a bacterial cell
- When a virus **replicates**, it uses the **host cell's mechanisms** for transcription, translation and other metabolic pathways, so not even these processes can be targeted as antibiotics do not bind to the proteins that host cells use in these processes
 - Drugs that would target these processes would **damage the host cells** and cause even more harm
- **Antivirals** are drugs that target viral **enzymes** without harming the host cell

6.3.5 Antibiotic Resistance


Antibiotic Resistance

- Within a bacterial population, there is **variation** caused by **mutations** (as occurs in populations of all species)
- A chance mutation might cause some bacteria to become **resistant** to an antibiotic (eg. penicillin)
 - When the population is treated with this antibiotic, **the resistant bacteria do not die**
 - This means the resistant bacteria can continue to reproduce with **less competition from the non-resistant bacteria**, which are now dead
- Therefore the **genes for antibiotic resistance are passed on** with a much greater frequency to the next generation
 - As bacteria only have one copy of each gene, a mutant gene will have an immediate effect on any bacterium possessing it
- Over time, the whole population of bacteria becomes **antibiotic-resistant** because the antibiotic-resistant bacteria are best suited to their environment
- This is an example of **evolution by natural selection**
- Some pathogenic bacteria have become **resistant to penicillin** as they have acquired **genes that code for the production of the enzyme β -lactamase** (also known as penicillinase), which breaks down penicillin


1 A POPULATION OF BACTERIA IN THE GUT. SOME HAVE ANTIBIOTIC RESISTANCE






2 WHEN EXPOSED TO AN ANTIBIOTIC, BACTERIA CAUSING ILLNESS, AS WELL AS HEALTHY GUT BACTERIA, ARE KILLED




3 WITH REDUCED COMPETITION FOR NUTRIENTS, ANTIBIOTIC-RESISTANT BACTERIA MULTIPLY, FORMING A LARGER POPULATION THAT IS DIFFICULT TO CONTROL



KEY:

 = PATHOGENIC, ANTIBIOTIC RESISTANT, BACTERIUM	 = HEALTHY GUT BACTERIUM
 = PATHOGENIC BACTERIUM	

PLASMIDS WITH ANTIBIOTIC-RESISTANT GENES CAN BE SHARED BETWEEN BACTERIA OF BOTH THE SAME AND DIFFERENT SPECIES.



Copyright © 2024 Exam Papers Practice

Bacteria evolve rapidly as they reproduce quickly and acquire random mutations – some of which confer resistance

The future of antibiotic resistance



- Antibiotic-resistant strains are a major problem in human medicine
- New resistant strains are constantly emerging due to the **overuse of antibiotics**
 - By using antibiotics frequently, humans exert a **selective pressure** on the bacteria, which supports the evolution of antibiotic resistance
- Scientists are trying hard to find **new antibiotics** that bacteria have not yet been exposed to, but this process is expensive and time-consuming
- Some strains of bacteria, such as methicillin-resistant *Staphylococcus aureus* (MRSA), can be **resistant to multiple antibiotics** and they create infections and diseases which are very difficult to treat
- When antibiotics were discovered, scientists thought they would be able to **eradicate** bacterial infections, but less than a century later a future is being imagined where many bacterial infections cannot be treated with current medicines

Measures to avoid antibiotic resistance

- Antibiotic resistance in bacteria is an example of natural selection that humans have helped to develop through **incorrect use or overuse** of antibiotics
- Implementation of certain measures can help to avoid antibiotic resistance. These measures may include:
 - Avoiding prescription of antibiotics for **non-serious or non-bacterial infections**
 - **Completing the full prescribed course** of antibiotics to ensure the infection is completely cleared
 - Maintaining **high standards of hygiene** in the hospital environment
 - Minimising use of antibiotics for routine treatment to animals in **agriculture**
 - Development of **new types of antibiotic**